Tumor cell expression of B7-H4 correlates with higher frequencies of tumor-infiltrating APCs and higher CXCL17 expression in human epithelial ovarian cancer.
B7-H4
CXCL17
epithelial ovarian cancer
immune infiltration
tumor infiltration
Journal
Oncoimmunology
ISSN: 2162-4011
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
Historique:
received:
03
04
2019
revised:
29
08
2019
accepted:
31
08
2019
entrez:
20
11
2019
pubmed:
20
11
2019
medline:
20
11
2019
Statut:
epublish
Résumé
B7-H4, an immune suppressive member of the B7 family, is highly expressed in a wide variety of human malignancies making it an attractive immunotherapeutic target. However, the association between B7-H4 expression in the tumor microenvironment and the immune infiltrate has not been comprehensively examined. To evaluate the immune tumor microenvironment, we analyzed epithelial ovarian tumors from 28 patients using flow cytometry, immunohistochemistry, functional, and genomic analyses. We determined B7-H4 expression patterns and compared the immune infiltrates of tumors with high and low surface expression of B7-H4. Frequencies and phenotypes of tumor and immune cells were determined using multiple flow cytometry panels. Immunohistochemistry was used to analyze cellular infiltration and location. Publicly available datasets were interrogated to determine intratumoral cytokine and chemokine expression. We found that B7-H4 was predominantly expressed by tumor cells in the epithelial ovarian tumor microenvironment. Surface expression of B7-H4 on tumor cells was correlated with higher levels of infiltrating mature antigen-presenting cells. Further, expression of CXCL17, a monocyte and dendritic cell chemoattractant, correlated strongly with B7-H4 expression. T cells expressed activation markers, but T cells expressing a combination of markers associated with T cell activation/exhaustion phenotype were not prevalent. Overall, our data suggest that B7-H4 is associated with a pro-inflammatory tumor microenvironment.
Identifiants
pubmed: 31741762
doi: 10.1080/2162402X.2019.1665460
pii: 1665460
pmc: PMC6844312
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e1665460Informations de copyright
© 2019 The Author(s). Published by Taylor & Francis.
Références
Immunity. 2003 Jun;18(6):863-73
pubmed: 12818166
Gynecol Oncol. 2006 Jan;100(1):44-52
pubmed: 16256178
Cancer Sci. 2016 Jul;107(7):944-54
pubmed: 27088889
Clin Cancer Res. 2017 Jun 15;23(12):2934-2941
pubmed: 28325750
J Biol Chem. 1997 Dec 19;272(51):32078-83
pubmed: 9405404
J Clin Invest. 2012 May;122(5):1628-43
pubmed: 22505455
Clin Cancer Res. 2016 Jun 1;22(11):2778-2790
pubmed: 27001312
Nucleic Acids Res. 2012 Jan;40(Database issue):D1144-9
pubmed: 22086960
Cell Rep. 2017 May 9;19(6):1189-1201
pubmed: 28494868
Cancer Med. 2016 Aug;5(8):1810-20
pubmed: 27292320
J Exp Med. 2006 Apr 17;203(4):871-81
pubmed: 16606666
J Immunol. 2012 Oct 15;189(8):4165-74
pubmed: 22972920
J Immunol. 2018 Aug 1;201(3):897-907
pubmed: 29898965
Immunity. 2003 Jun;18(6):849-61
pubmed: 12818165
N Engl J Med. 2003 Jan 16;348(3):203-13
pubmed: 12529460
Clin Cancer Res. 2017 Jan 15;23(2):370-378
pubmed: 27440266
Cancer Immunol Res. 2015 Feb;3(2):184-95
pubmed: 25527357
Gynecol Oncol. 2017 Jun;145(3):446-452
pubmed: 28347512
PLoS One. 2012;7(8):e44080
pubmed: 22952881
DNA Cell Biol. 1997 Oct;16(10):1249-56
pubmed: 9364936
Cytokine. 2016 Nov;87:37-45
pubmed: 27498604
Cancer Res. 2007 Sep 15;67(18):8900-5
pubmed: 17875732
Biochem Biophys Res Commun. 2006 Nov 10;350(1):74-81
pubmed: 16989774
Nat Rev Cancer. 2015 Nov;15(11):668-79
pubmed: 26493647
J Clin Invest. 2014 May;124(5):2246-59
pubmed: 24667641
Clin Cancer Res. 2018 Oct 15;24(20):5037-5047
pubmed: 30084834
J Immunol. 2014 Aug 1;193(3):1468-74
pubmed: 24973458
PLoS One. 2011 Apr 13;6(4):e18064
pubmed: 21533284
Int J Clin Oncol. 2015 Apr;20(2):273-81
pubmed: 24804867
Clin Cancer Res. 2017 Sep 1;23(17):5202-5209
pubmed: 28539467
Oncotarget. 2017 Sep 20;8(47):82740-82753
pubmed: 29137299
Cancer J. 2016 Mar-Apr;22(2):101-7
pubmed: 27111905
Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43
pubmed: 16344461
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Gynecol Oncol. 2007 Jul;106(1):119-27
pubmed: 17509674
J Am Soc Nephrol. 2010 Jun;21(6):933-42
pubmed: 20299353
Nat Rev Immunol. 2015 Aug;15(8):486-99
pubmed: 26205583
Blood. 2012 Mar 8;119(10):2284-92
pubmed: 22234694
Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10388-92
pubmed: 12920180
Clin Cancer Res. 2015 Oct 1;21(19):4257-61
pubmed: 26187614
N Engl J Med. 2004 Dec 9;351(24):2519-29
pubmed: 15590954
Oncogene. 2013 Nov 14;32(46):5347-58
pubmed: 23318460
J Immunol. 2017 May 15;198(10):3897-3908
pubmed: 28389593
Oncotarget. 2017 Mar 21;8(12):18861-18871
pubmed: 28061481
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
J Clin Invest. 2012 May;122(5):1615-27
pubmed: 22505458
Immunity. 2018 Apr 17;48(4):773-786.e5
pubmed: 29625896
Gastroenterology. 2011 Jan;140(1):310-21
pubmed: 20955708
J Immunol. 2006 Feb 15;176(4):2069-73
pubmed: 16455961
Cancer Res. 1991 Apr 1;51(7):1934-9
pubmed: 2004379
Clin Cancer Res. 1995 May;1(5):501-7
pubmed: 9816009
Clin Cancer Res. 2008 Aug 15;14(16):5198-208
pubmed: 18698038